Intellect Neurosciences, Inc.
(Public, OTC:ILNS) Watch this stockFind more results for
ILNS
Advertisement
Key stats and ratios
| Q3 (Sep '08) | 2008 | |
| Net profit margin | 172.40% | - |
| Operating margin | -27.80% | - |
| EBITD margin | - | - |
| Return on average assets | 835.64% | 1257.21% |
| Return on average equity | - | - |
| Employees | 8 | - |
Address
Website links
Intellect Neurosciences, Inc. discussed on blogs
Rhoads Research Lecture and Awards Ceremony - Rhoads, Research ...
- sciencestage.com
- 35 minutes ago
McMaster Daily News
- McMaster University - Daily News Headlines
- Nov 20, 2009
Robotics & Automation: FROM ANIMALS TO ANIMATS 11, The 11th ...
- V2
- Robotics & Automation
- Nov 20, 2009
Intellect Neurosciences, Inc. discussions
View all discussions »Description
Intellect Neurosciences, Inc. (Intellect) is a biopharmaceutical company developing and advancing a patent portfolio related to specific therapeutic approaches for treating Alzheimer’s disease (AD). In addition, the Company is developing drug candidates to treat AD and other diseases associated with oxidative stress. Its product line includes OXIGON, IN-N01 (ANTISENILIN) and (RECALL-VAX). The Company’s subsidiary is Intellect USA, Inc.
Officers and directors
| Daniel G. Chain Ph.D. | Chairman of the Board, Chief Executive Officer | |
| Elliot M. Maza J.D. CPA | President, Chief Financial Officer, Director | |
| Kelvin Davies Ph.D. | Director | |
| William P. Keane | Director | |
| Harvey L. Kellman | Director | |
| Kathleen P. Mullinix Ph.D. | Director |